2023-03-23 00:58:07 ET
Summary
- Arcus’s pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody.
- Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study.
- The consistency of the efficacy and safety data from both of the domvanalimab-containing arms observed at this interim analysis support the continued strong conviction in the domvanalimab program.
- Arcus has a solid financial position with ample cash to support its development programs and is well-positioned to execute on its strategic initiatives.
For further details see:
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results